Citations

Mayo Clinic

Showing 10 of 108537 citations.

Successful treatment of actinic prurigo with baricitinib in an 8‐year‐old child: A case report
Malekan, Mohammad , Aghazadeh, Nessa , Rokni, Ghasem Rahmatpour , Babaei, Mahsa , Montazer, Fatemeh , Gholizadeh, Nasim , Aghazadeh Mohandesi, Nessa

Pediatric Dermatology | April 29, 2024 | Volume: 41 | Issue: 6 | Pages: 1159-1161

10.1111/pde.15643 | PMID 38684232 Get It

Abstract Actinic prurigo is a rare photodermatosis characterized by pruritic papulonodular lesions. Treatment is challenging, especially in children, as sun protection strategies need to be rigorously implemented and symptoms often persist throughout the year. Herein, we present a case of actinic prurigo in an 8‐year‐old patient with rapid and successful relief with baricitinib.
Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma
Tine, Brian A. Van , Ingham, Matthew , Attia, Steven , Meyer, Christian F. , Baird, John D. , Brooks-Asplund, Esther M. , D'Silva, Dhiren, Kong, Ronald , Mwatha, Anthony, O’Keefe, Kylie, Weetall, Marla , Spiegel, Robert J. , Van Tine, Brian A , Ingham, Matthew A , Brooks-Asplund, Esther , Schwartz, Gary K , Meyer, Christian , Schwartz, Gary K.

Journal of Clinical Oncology | April 29, 2024 | Volume: 42 | Issue: 20 | Pages: 2404-2414

10.1200/jco.23.01684 | PMID 38684039 Get It

PURPOSE This multicenter, single-arm, open-label, phase Ib study was designed to determine the recommended phase II dose (RP2D) and to evaluate the safety and preliminary efficacy of unesbulin plus dacarbazine (DTIC) in patients with advanced leiomyosarcoma (LMS). PATIENTS AND METHODS Adult subjects with locally advanced, unresectable or metastatic, relapsed or refractory LMS were treated with escalating doses of unesbulin orally twice per week in combination with DTIC 1,000 mg/m2 intravenously (IV) once every 21 days. The time-to-event continual reassessment method was used to determine the RP2D on the basis of dose-limiting toxicities (DLTs) assessed during the first two 21-day treatment cycles. All explored doses of unesbulin (200 mg up to 400 mg) were in combination with DTIC. An expansion cohort was enrolled to evaluate the safety and efficacy of unesbulin at the RP2D. RESULTS Unesbulin 300 mg administered orally twice per week in combination with DTIC 1,000 mg/m2 IV once every 21 days was identified as the RP2D. On the basis of data from 27 subjects who were deemed DLT-evaluable, toxicity was higher in the unesbulin 400 mg group, with three of four subjects (75%) experiencing DLTs versus one of four subjects (25%) in the 200 mg group and three of 19 subjects (15.8%) in the 300 mg group. The most commonly reported DLTs and treatment-related grade 3 and 4 adverse events were thrombocytopenia and neutropenia. At the RP2D, seven subjects who were efficacy evaluable achieved partial response for an objective response rate of 24.1%. CONCLUSION Unesbulin 300 mg twice per week plus DTIC 1,000 mg/m2 once every 21 days was identified as the RP2D, demonstrating a favorable benefit-risk profile in a heavily pretreated population of adults with advanced LMS.
Stiff right atrial syndrome? A complex clinical case report utilizing multimodality imaging and invasive hemodynamics
Krishnarao, Krithika , Yip, D. , Goswami, Rohan , Leoni, Juan , Patel, Parag C. , Yip, Daniel S , Goswami, Rohan M , Leoni, Juan Carlos , Patel, Parag C. , Goswami, Rohan

European Heart Journal - Case Reports | April 29, 2024 | Volume: 8 | Issue: 4 | Pages: No page available

10.1093/ehjcr/ytae163 | PMID 38690555 Get It

Abstract Background Stiff left atrial syndrome is a well-established cause of heart failure symptoms. A parallel entity involving the right atrium (RA) has not previously been described. We present a case of refractory right heart failure (RHF) 12 years following orthotopic heart transplantation. Case summary Patient underwent annuloplasty ring placement for severe tricuspid regurgitation in 2018 and kidney transplantation in 2020. The use of multimodality imaging and a multidisciplinary approach suggested a stiff RA as a potential etiology to refractory symptoms. Redo-heart and kidney transplantation in March 2021 led to the resolution of symptoms without recurrence. Discussion We propose stiff right atrial syndrome that may need to be considered in the setting of refractory RHF primarily suggested by significant right atrial enlargement and restrictive physiology.
DMAeEDNet: Dense Multiplicative Attention Enhanced Encoder Decoder Network for Ultrasound-Based Automated Breast Lesion Segmentation
Saini, Manali , Afrin, Humayra , Korani, Setayesh Sotoudehnia , Fatemi, Mostafa , Sotoudehnia, Setayesh , Alizad, Azra , Fatemi, Mostafa , Alizad, Azra

IEEE Access | April 29, 2024 | Volume: 12 | Issue: No issue available | Pages: 60541-60555

10.1109/access.2024.3394808 | PMID 39553390 Get It

A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Mezzanotte-Sharpe, Jessica , O’Neill, Anne, Arteaga, Carlos L. , Yang, Ximing J. , Cella, David , Meropol, Neal J. , Alpaugh, R. Katherine , Saphner, Thomas J. , Swaney, Robert E., Hoelzer, Karen L., Gradishar, William J. , Sundaram, P. Kothai, Jilani, Shamim Z., Perez, Edith A. , Jahanzeb, Mohammad , Reid, Sonya , Mayer, Ingrid A. , Wagner, Lynne I. , Abramson, Vandana G. , Lin, Nancy U. , Wolff, Antonio C. , Sledge, George W.

No container title available | April 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4295044/v1 | PMID 38746356 Get It

Abstract Background In 2008, bevacizumab received accelerated Food and Drug Administration (FDA) approval for use in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Based on the preclinical and preliminary clinical activity of the trastuzumab and bevacizumab combination, ECOG-ACRIN E1105 trial was developed to determine if the addition of bevacizumab to a chemotherapy and trastuzumab combination for first-line therapy would improve progression-free survival (PFS) in patients with HER2-positive MBC. Findings: 96 patients were randomized to receive standard first-line chemotherapy and trastuzumab with or without bevacizumab between November 2007 and October 2009, and 93 began protocol therapy. Induction therapy was given for 24 weeks, followed by maintenance trastuzumab with or without bevacizumab. 60% (56/93) began carboplatin and 74% (69/93) completed 6 cycles of induction therapy. Primary endpoint was PFS. Median PFS was 11.1 and 13.8 months for placebo and bevacizumab arms, respectively (hazard ratio [HR] 95%, Confidence Interval [Cl] for bevacizumab vs. placebo: 0.73 [0.43–1.23], p = 0.24), and at a median follow-up of 70.7 months, median survival was 49.1 and 63 months (HR [95% Cl] for OS: 1.09 [0.61–1.97], p = 0.75). The most common toxicities across both arms were neutropenia and hypertension, with left ventricular systolic dysfunction, fatigue, and sensory neuropathy reported more frequently with bevacizumab. Conclusions In this trial, the addition of bevacizumab did not improve outcomes in patients with metastatic HER2-positive breast cancer. Although the trial was underpowered due to smaller than anticipated sample size, these findings corroborated other clinical trials during this time.
Validation of the Learner Engagement Instrument for Continuing Professional Development
Cook, David A. , Stephenson, Christopher R.

Academic Medicine | April 29, 2024 | Volume: 99 | Issue: 9 | Pages: 1024-1031

10.1097/acm.0000000000005749 | PMID 38683885 Get It

Abstract Purpose Learner engagement is the energy learners exert to remain focused and motivated to learn. The Learner Engagement Instrument (LEI) was developed to measure learner engagement in a short continuing professional development (CPD) activity. The authors validated LEI scores using validity evidence of internal structure and relationships with other variables. Method Participants attended 1 of 4 CPD courses (1 in-person, 2 online livestreamed, and 1 either in-person or livestreamed) in 2018, 2020, 2021, and 2022. Confirmatory factor analysis was used to examine model fit for several alternative structural models, separately for each course. The authors also conducted a generalizability study to estimate score reliability. Associations were evaluated between LEI scores and Continuing Medical Education Teaching Effectiveness (CMETE) scores and participant demographics. Statistical methods accounted for repeated measures by participants. Results Four hundred fifteen unique participants attended 203 different CPD presentations and completed the LEI 11,567 times. The originally hypothesized 4-domain model of learner engagement (domains: emotional, behavioral, cognitive in-class, cognitive out-of-class) demonstrated best model fit in all 4 courses, with comparative fit index ≥ 0.99, standardized root mean square residual ≤ 0.031, and root mean square error of approximation ≤ 0.047. The reliability for overall scores and domain scores were all acceptable (50-rater G-coefficient ≥ 0.74) except for the cognitive in-class domain (50-rater G-coefficient of 0.55 to 0.66). Findings were similar for both in-person and online delivery modalities. Correlation of LEI scores with teaching effectiveness was confirmed (rho=0.58), and a small correlation was found with participant age (rho=0.19); other associations were small and not statistically significant. Using these findings, we generated a shortened 4-item instrument, the LEI Short Form. Conclusions This study confirms a 4-domain model of learner engagement and provides validity evidence that supports using LEI scores to measure learner engagement in both in-person and livestreamed CPD activities.
Bypassing the Brick-and-Mortar Hospital: Increasing Direct Admissions from the Emergency Department to Inpatient Hospital-at-Home
Webster, Leah W., Cox, Matt D., Fazio, Jacey R., Felix, Heidi, Greenwell, Holly R., Botella, R, Grek, Ami , Felix, Heidi M, Botella, Rachel M, Grek, Ami A., Cox, Matthew D. , Felix, Heidi M., Maniaci, Michael J.

American Journal of Medical Quality | April 29, 2024 | Volume: 39 | Issue: 3 | Pages: 99-104

10.1097/jmq.0000000000000186 | PMID 38683730 Get It

Home hospital programs continue to grow across the United States. There are limited studies around the process of patient selection and successful acquisition from the emergency department. The article describes how an interdisciplinary team used quality improvement methodology to significantly increase the number of admissions directly from the emergency department to the Advanced Care at Home program.
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease
Wagemann, Olivia , Shi, Xinyu , Bittner, Tobias , Scelsi, Marzia A. , Farlow, Martin R. , Clifford, David B. , Santacruz, Anna , Aschenbrenner, Andrew J. , Hassenstab, Jason , Gordon, Brian A. , Coalier, Kelley A., Perrin, Richard J., Xiong, Chengjie , Li, Yan , Morris, John C. , Lah, James J., Berman, Sarah , Roberson, Erik D. , Dyck, Christopher H. van, Gauthier, Serge , Pariente, Jérémie , Mummery, Catherine J. , Day, Gregory S. , Ringman, John M. , Méndez, Patricio Chrem, Fox, Nick C. , Okhravi, Hamid , Chhatwal, Jasmeer P. , Xiong, Chengjie , Sims, John R. , Holdridge, Karen C. , Proctor, Nicholas K. , Yaari, R. , Andersen, Scott W. , Mancini, Michele , Unit, Dominantly Inherited Alzheimer Network–Trials, Daniels, Alisha , Courtney, Laura, Lu, Ruijin , Gremminger, Emily, Franklin, Erin , Jerome, Gina, Herries, Elizabeth, Baker, Bryce, Minton, Matthew, Goate, Alison , Picarello, Danielle M. , Hornbeck, Russ C. , Chen, Allison , Chen, Charles D., Jarman, Steve, Jackson, Kelley, Keefe, Sarah , Koudelis, Deborah, Massoumzadeh, Parinaz , Nicklaus, Joyce , Pulizos, Christine, Sabaredzovic, Edita, Smith, Hunter , Scott, Jalen , Simmons, Ashlee, Rizzo, Jacqueline, Barthélemy, Nicolas R. , Xu, Jinbin , Ikonomović, Snežana, Nadkarni, Neelesh K. , Graff‐Radford, Neill R. , Huey, Edward D. , Salloway, Stephen , Bechara, Jacob , Ryan, Natalie S. , Laske, Christoph , Hofmann, Anna, Kuder-Buletta, Elke, Gräber‐Sultan, Susanne, Obermueller, Ulrike, Roedenbeck, Yvonne, Sánchez‐Valle, Raquel , Vázquez, Silvia , Leon, Yudy Milena, Ramírez, Laura, Seyfried, Nicholas T. , Fagan, Anne M. , Mori, Hiroshi , Gordon, Brian A , Roberson, Erik , Sánchez-Valle, Raquel , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Aschenbrenner, Andrew J , Goate, Alison M , Berman, Sarah , Liu, Haiyan , Wang, Guoqiao , Supnet, Charlene , Benzinger, Tammie L.S. , Cruchaga, Carlos , Ibanez, Laura , Li, Yan, Dyck, Christopher H. van , Galasko, Douglas , Hsiung, Ging‐Yuek Robin , Brooks, William S. , George‐Hyslop, Peter St , Suzuki, Kazushi , Jucker, Mathias , Mancini, Michele, Llibre‐Guerra, Jorge J. , Bateman, Randall J. , McDade, Eric , Unit, Dominantly Inherited Alzheimer Network–Trials, Xu, Xiong, Stauber, Jennifer, Renton, Alan , Flores, Shaney , Joseph‐Mathurin, Nelly , McCullough, Austin , McKay, Nicole S. , Wáng, Qīng , Smith, Jennifer A. , Stout, Sarah Holtz , Karch, Celeste M. , Marsh, Jacob A. , Holtzman, David M. , Noble, James M. , Ikeuchi, Takeshi , Kasuga, Kensaku , Niimi, Yoshiki , Schofield, Peter R. , Martins, Ralph N. , Cash, David M. , Vöglein, Jonathan , Lee, Jae‐Hong , Roh, Jee Hoon , Rosa-Neto, Pedro , Allegri, Ricardo , Surace, Ezequiel , Lopera, Francisco Javier , Aguillon, David , Levey, Allan I. , Johnson, Erik C. B. , Masters, Colin L.

JAMA Neurology | April 29, 2024 | Volume: 81 | Issue: 6 | Pages: 582

10.1001/jamaneurol.2024.0991 | PMID 38683602 Get It

Importance Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD). Objective To investigate longitudinal biomarker changes of synaptic dysfunction, neuroinflammation, and neurodegeneration in individuals with DIAD who are receiving antiamyloid treatment. Design, Setting, and Participants From 2012 to 2019, the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU-001) study, a double-blind, placebo-controlled, randomized clinical trial, investigated gantenerumab and solanezumab in DIAD. Carriers of gene variants were assigned 3:1 to either drug or placebo. The present analysis was conducted from April to June 2023. DIAN-TU-001 spans 25 study sites in 7 countries. Biofluids and neuroimaging from carriers of DIAD gene variants in the gantenerumab, solanezumab, and placebo groups were analyzed. Interventions In 2016, initial dosing of gantenerumab, 225 mg (subcutaneously every 4 weeks) was increased every 8 weeks up to 1200 mg. In 2017, initial dosing of solanezumab, 400 mg (intravenously every 4 weeks) was increased up to 1600 mg every 4 weeks. Main Outcomes and Measures Longitudinal changes in CSF levels of neurogranin, soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase 3–like 1 protein (YKL-40), glial fibrillary acidic protein (GFAP), neurofilament light protein (NfL), and plasma levels of GFAP and NfL. Results Of 236 eligible participants screened, 43 were excluded. A total of 142 participants (mean [SD] age, 44 [10] years; 72 female [51%]) were included in the study (gantenerumab, 52 [37%]; solanezumab, 50 [35%]; placebo, 40 [28%]). Relative to placebo, gantenerumab significantly reduced CSF neurogranin level at year 4 (mean [SD] β = −242.43 [48.04] pg/mL; P < .001); reduced plasma GFAP level at year 1 (mean [SD] β = −0.02 [0.01] ng/mL; P = .02), year 2 (mean [SD] β = −0.03 [0.01] ng/mL; P = .002), and year 4 (mean [SD] β = −0.06 [0.02] ng/mL; P < .001); and increased CSF sTREM2 level at year 2 (mean [SD] β = 1.12 [0.43] ng/mL; P = .01) and year 4 (mean [SD] β = 1.06 [0.52] ng/mL; P = .04). Solanezumab significantly increased CSF NfL (log) at year 4 (mean [SD] β = 0.14 [0.06]; P = .02). Correlation analysis for rates of change found stronger correlations between CSF markers and fluid markers with Pittsburgh compound B positron emission tomography for solanezumab and placebo. Conclusions and Relevance This randomized clinical trial supports the importance of fibrillar amyloid reduction in multiple AD-related processes of neuroinflammation and neurodegeneration in CSF and plasma in DIAD. Additional studies of antiaggregated amyloid therapies in sporadic AD and DIAD are needed to determine the utility of nonamyloid biomarkers in determining disease modification. Trial Registration ClinicalTrials.gov Identifier: NCT04623242
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer
Chen, Wendy Y. , Hahn, Olwen, Briccetti, Frederick , Irvin, William , Symington, Banu , Visvanathan, Kala , Pohlmann, Paula R. , Openshaw, Thomas H. , Weiss, Anna , Visvanathan, Kala , Pohlmann, Paula , Ballman, Karla V. , Partridge, Ann H. , Winer, Eric P. , Carey, Lisa A. , Holmes, Michelle D

JAMA | April 29, 2024 | Volume: 331 | Issue: 20 | Pages: 1714

10.1001/jama.2024.4840 | PMID 38683596 Get It

Importance Observational studies of survivors of breast cancer and prospective trials of aspirin for cardiovascular disease suggest improved breast cancer survival among aspirin users, but prospective studies of aspirin to prevent breast cancer recurrence are lacking. Objective To determine whether aspirin decreases the risk of invasive cancer events among survivors of breast cancer. Design, Setting, and Participants A011502, a phase 3, randomized, placebo-controlled, double-blind trial conducted in the United States and Canada with 3020 participants who had high-risk nonmetastatic breast cancer, enrolled participants from 534 sites from January 6, 2017, through December 4, 2020, with follow-up to March 4, 2023. Interventions Participants were randomized (stratified for hormone receptor status [positive vs negative], body mass index [≤30 vs >30], stage II vs III, and time since diagnosis [<18 vs ≥18 months]) to receive 300 mg of aspirin (n = 1510) or placebo once daily (n = 1510) for 5 years. Main Outcomes and Measures The primary outcome was invasive disease–free survival. Overall survival was a key secondary outcome. Results A total of 3020 participants were randomized when the data and safety monitoring committee recommended suspending the study at the first interim analysis because the hazard ratio had crossed the prespecified futility bound. By median follow-up of 33.8 months (range, 0.1-72.6 months), 253 invasive disease–free survival events were observed (141 in the aspirin group and 112 in the placebo group), yielding a hazard ratio of 1.27 (95% CI, 0.99-1.63; P = .06). All invasive disease–free survival events, including death, invasive progression (both distant and locoregional), and new primary events, were numerically higher in the aspirin group, although the differences were not statistically significant. There was no difference in overall survival (hazard ratio, 1.19; 95% CI, 0.82-1.72). Rates of grades 3 and 4 adverse events were similar in both groups. Conclusion and Relevance Among participants with high-risk nonmetastatic breast cancer, daily aspirin therapy did not improve risk of breast cancer recurrence or survival in early follow-up. Despite its promise and wide availability, aspirin should not be recommended as an adjuvant breast cancer treatment. Trial Registration ClinicalTrials.gov Identifier: NCT02927249
Use of Fluorescence Imaging in Liver Transplant Surgery
Ducás, Alvaro , Evans, Lorna A. , Laos, Emiliano G. Manueli , Giovinazzo, Francesco , Group, on behalf of the SMAGEICS, Evans, Lorna A , Manueli Laos, Emiliano G , Giovinazzo, Francesco , Martinino, Alessandro , Group, on behalf of the SMAGEICS

Journal of Clinical Medicine | April 29, 2024 | Volume: 13 | Issue: 9 | Pages: 2610

10.3390/jcm13092610 | PMID 38731139 Get It

Liver transplant surgery is a complex procedure that demands high knowledge of surgical anatomy and the precise recognition and preservation of structures. To address this, the use of fluorescence imaging has facilitated the identification of anatomical structures such as biliary ducts, arteries, and liver segmentation. Indocyanine green is among the most commonly utilized fluorescent agents, not just during surgery but also in the pre- and postoperative phases, where it is used to assess graft failure by measuring the plasma disappearance rate. New advancements such as artificial intelligence paired with fluorescence imaging have the potential to enhance patient outcomes. Additionally, technologies such as augmented reality and mixed reality could be integrated into surgical procedures, broadening the scope of possibilities for improving patient safety.